Evidence map›Paper›PMID 40632201›Full record

ArticleAnnals of surgical oncology2025

Preoperative Systemic Immune-Inflammatory Index Predicts Occult Nodal Disease in Clinically Node-Negative Intrahepatic Cholangiocarcinoma.

Jun Kawashima, Miho Akabane, Mujtaba Khalil, Selamawit Woldesenbet, Odysseas P Chatzipanagiotou, Yutaka Endo, Kota Sahara, François Cauchy, Federico Aucejo, Hugo P Marques and 18 more

Abstract read
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Jun KawashimaDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Miho AkabaneDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Mujtaba KhalilDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Selamawit WoldesenbetDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Odysseas P ChatzipanagiotouDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Yutaka EndoDepartment of Transplant Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Kota SaharaDepartment of Gastroenterological Surgery, Yokohama City University, Yokohama, Japan.
François CauchyDepartment of HPB Surgery and Liver Transplantation, Beaujon Hospital, Clichy, France.
Federico AucejoDepartment of Hepato-pancreato-biliary & Liver Transplant Surgery, Cleveland Clinic Foundation, Digestive Diseases and Surgery Institute, Cleveland, OH, USA.
Hugo P MarquesDepartment of Surgery, Curry Cabral Hospital, Lisbon, Portugal.
Rita LopesDepartment of Surgery, Curry Cabral Hospital, Lisbon, Portugal.
Andreia RodrigueaDepartment of Surgery, Curry Cabral Hospital, Lisbon, Portugal.
Tom HughDepartment of Surgery, The University of Sydney, Sydney, NSW, Australia.
Feng ShenDepartment of Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Shishir K MaithelDivision of Surgical Oncology, Winship Cancer Institution, Emory University, Atlanta, GA, USA.
Bas Groot KoerkampDepartment of Surgery, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Irinel PopescuDepartment of Surgery, Fundeni Clinical Institute, Bucharest, Romania.
Minoru KitagoDepartment of Surgery, Keio University, Tokyo, Japan.
Matthew J WeissDepartment of Surgery, Cancer Institute, New Hyde Park, Northwell Health, NY, USA.
Guillaume MartelDepartment of Surgery, University of Ottawa, Ottawa, ON, Canada.
Carlo PulitanoDepartment of Surgery, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Luca AldrighettiDepartment of Surgery, San Raffaele Hospital, Milan, Italy.
George PoultsidesDepartment of Surgery, Stanford University, Stanford, CA, USA.
Andrea RuzzenteDivision of General and Hepatobiliary Surgery, University of Verona, Verona, Italy.
Todd W BauerDepartment of Surgery, University of Virginia, Charlottesville, VA, USA.
Ana GleisnerDepartment of Surgery, University of Colorado Denver, Denver, CO, USA.
Itaru EndoDepartment of Gastroenterological Surgery, Yokohama City University, Yokohama, Japan.
Timothy M PawlikDepartment of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA. Tim.Pawlik@osumc.edu.ORCID http://orcid.org/0000-0002-7994-9870

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate preoperative diagnosis of nodal status in intrahepatic cholangiocarcinoma (ICC) remains challenging. The objective of the current study was to determine if the systemic immune-inflammatory index (SII) was associated with occult nodal disease (OND) among cN0 patients undergoing resection for ICC.

methodsPatients who underwent curative resection for ICC were identified from an international multi-institutional database. A multivariable logistic regression model was used to assess the relationship between SII and OND.

resultsAmong 490 patients who underwent curative resection with lymph node dissection (LND) for cN0 ICC, 135 (27.6%) had OND. Among these individuals, high SII (≥738.4) was independently associated with OND (odds ratio [OR], 1.85, 95% confidence interval [CI], 1.18-2.92). This association was consistent even among patients with cT1aN0M0 disease (OR, 1.85; 95% CI, 1.19-2.88). Interestingly, among patients with high SII and N0/Nx disease, individuals whose total number of lymph nodes examined (TLNE) was fewer than six had worse 3-year recurrence-free survival (RFS) than patients with a TLNE of six or more (38.8% vs 74.0%; p = 0.002). In contrast, RFS did not differ among patients with low SII and N0/Nx disease (TLNE <6 [49.1%] vs ≥6 [62.4%]; p = 0.099).

conclusionsHigh SII was an independent predictor of OND, even among patients with early-stage disease, suggesting that incorporating SII into preoperative risk assessment may refine staging and guide treatment strategies including the need for neoadjuvant therapy as well as the extent and adequacy of LND.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaInflammationLymph NodesAgedFemaleFollow-Up StudiesHumansLymphatic MetastasisLymph Node ExcisionMaleMiddle AgedPreoperative CarePreoperative PeriodPrognosisRetrospective Studies

Identifiers

PMID40632201
PMCPMC12454466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.